Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateTopicMedicinesCOVID-19Compliance and inspectionsAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxPaediatricsParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesReferralsRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVaccinesVeterinary limited marketsDiseases areaCancerCardiovascular diseasesDiabetesHIV and AIDSImmune-system diseasesNeurodegenerative diseasesTreatment of human immunodeficiency virus type 1 (HIV-1) infectionViral diseasesResponsible bodyCHMPCATCMDhCOMPCVMPHMPCManagement BoardPDCOPRACPatient safetyYesFiltersResults (14) RoActemraSort byLast update date (new to old)Last update date (old to new)A-ZZ-AETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19MedicinesEMA recommends approval for use of RoActemra in adults with severe COVID-196 December 2021NewsHumanCOVID-19MedicinesEMA starts evaluating use of RoActemra in hospitalised adults with severe COVID-1916 August 2021NewsHumanCOVID-19Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 201821 September 2018NewsHumanMedicinesFirst two CAR-T cell medicines recommended for approval in the European Union29 June 2018Press releaseHumanMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 201829 June 2018NewsHumanMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 201721 July 2017NewsHumanMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 201624 June 2016NewsHumanMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 201425 July 2014NewsHumanEuropean Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection19 November 2013Press releaseCorporateMedicines12Next
ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19Medicines
EMA recommends approval for use of RoActemra in adults with severe COVID-196 December 2021NewsHumanCOVID-19Medicines
EMA starts evaluating use of RoActemra in hospitalised adults with severe COVID-1916 August 2021NewsHumanCOVID-19
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 201821 September 2018NewsHumanMedicines
First two CAR-T cell medicines recommended for approval in the European Union29 June 2018Press releaseHuman
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 201829 June 2018NewsHuman
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 201721 July 2017NewsHuman
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 201624 June 2016NewsHuman
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 201425 July 2014NewsHuman
European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection19 November 2013Press releaseCorporateMedicines